Sort   by:  
 Page size 
UnknownTipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers.
Not available
S-EPMC6095730 | biostudies-literature
UnknownTipifarnib prevents development of hypoxia-induced pulmonary hypertension.
Not available
S-EPMC5408956 | biostudies-literature
GenomicA Phase 2 Study of Tipifarnib in Large Granular Lymphocyte (LGL) Leukemia

LGL leukemia can be divided into three subsets including the following: αβ or γδT-LGL and NK-LGL leukemia. All three subtypes will be enrolled using a two-stage design. The primary endpoint of the study is assessment of overall clinical response. Correlative laboratory studies...

phs000594 | dbGaP
GenomicsThe effect of c-Myc over-expression on the sensitivity to Tipifarnib treatment in three cancer cell lines
The effect of c-Myc over-expression on the sensitivity to Tipifarnib treatment in three cancer cell lines
PRJNA863472 | ENA
ProteomicsFunctional proteomics-based investigation of the cellular response to farnesyl transferase inhibition in lung cancer (tipifarnib treatment of lung cancer cells)
The subcellular localization of proteins can be highly dynamic and regulated by post-translational modifications. Farnesylation is a lipid modification that enables anchoring of proteins to cellular membranes, and thus, spatially resolved signaling and activity. Due to the importance of farnesylatio...
ORGANISM(S): Homo sapiens (Human) 
2025-05-13 | PXD050480 | Pride
Proteomics Tipifarnib Lung cancer Human Hirief Cell line Lc-ms/ms 
TranscriptomicsThe effect of c-Myc over-expression on the sensitivity to Tipifarnib treatment in three cancer cell lines
To investigate whether the over-expression of c-Myc gene can sensitize cancer cells of multiple tissue origins to Tipifarnib. We performed differential gene expression analysis using RNA-seq profile of three c-Myc over-expressed and control cell lines with/without Tipifarnib treatment.
ORGANISM(S): Homo sapiens 
2022-08-01 | GSE210029 | GEO
ProteomicsRepurposing Farnesyltransferase Inhibitors Tipifarnib and Lonafarnib as Antibacterial Agents: Proteomic and Functional Analyses
Farnesyltransferase inhibitors (FTIs) such as tipifarnib and lonafarnib were originally developed as anticancer agents but have recently been reported to exhibit antibacterial activity against Gram-positive pathogens. The underlying antibacterial mechanism of action, however, remains unknown. Here, ...
ORGANISM(S): Bacillus subtilis subsp. subtilis str. 168 Bacteria 
2026-09-14 | PXD081045 | Pride
Drug repurposing Mode of action Farnesyltransferase inhibitors Proteomics Antibiotics 
UnknownTipifarnib Reduces Extracellular Vesicles and Protects From Heart Failure.
Not available
S-EPMC11223950 | biostudies-literature
TranscriptomicsA two-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia
Currently there is no method available to predict response to farnesyltransferase inhibitors (FTI). We analyzed gene expression profiles from the bone marrow of patients from a phase 2 study of the FTI tipifarnib, in older adults with previously untreated acute myeloid leukemia (AML). The RASGRP1:AP...
ORGANISM(S): Homo sapiens 
2007-09-12 | GSE8970 | GEO
TranscriptomicsIdentification of molecular predictors of response in a study of tipifarnib treatment in relapsed and refractory AML
Gene signatures were derived to separate responders from nonresponders by tipifarnib treatment. Keywords: response analysis
ORGANISM(S): Homo sapiens 
2007-01-31 | GSE5122 | GEO
Sort   by:  
 Page size